NyakuAN, ZhengL, GulickRM, et al.: Dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA <500 000 copies/mL: Week 48 outcomes from ACTG 5353. J Antimicrob Chemother. 2019.
2.
CahnP, MaderoJS, ArribasJR, et al.: Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): Week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. Lancet, 2019; 393:143–155.
3.
JolyV, BurdetC, LandmanR, et al.: Dolutegravir and lamivudine maintenance therapy in HIV-1 virologically suppressed patients: Results of the ANRS 167 trial (LAMIDOL). J Antimicrob Chemother, 2019; 74:739–745.
4.
BaldinG, CicculloA, BorghettiA, Di GiambenedettoS: Virological efficacy of dual therapy with lamivudine and dolutegravir in HIV-1-infected virologically suppressed patients: Long-term data from clinical practice. J Antimicrob Chemother, 2019; 74:1461–1463.
